Corpus ID: 25477032

[Phase I clinical study of TT-62. Research group of TT-62].

  title={[Phase I clinical study of TT-62. Research group of TT-62].},
  author={T. Taguchi and H. Furue and H. Niitani and K. Ohta and S. Tsukagoshi and Akira Wakui and K. Hasegawa and I. Nakao and Y. Ohashi and T. Tominaga},
  journal={Gan to kagaku ryoho. Cancer & chemotherapy},
  volume={20 2},
  • T. Taguchi, H. Furue, +7 authors T. Tominaga
  • Published 1993
  • Medicine
  • Gan to kagaku ryoho. Cancer & chemotherapy
  • TT-62 is a new derivative of FdUMP, which is the active metabolite of 5-FU. A phase I clinical study of TT-62 was conducted by a cooperative study. The same patients received single and 2-week oral administration of TT-62. Starting from 60 mg/m2 (1n), the dose was escalated to 420 mg/m2 (7n). In the single administration, the maximum tolerated dose (MTD) could not be determined. In the 2-week administration, MTD was 420 mg/m2, and the dose limiting factor was gastro-intestinal disturbances such… CONTINUE READING
    1 Citations